IDC-009

N/A

Report date: 2023/08/24 17:34:16

First In Class

Base Information

Drug NameIDC-009

Drug Alias NameIDC-009IDC009

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effects

TargetsUpdating

Therapy Area/IndicationsOvarian NeoplasmsPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingapore

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPrestige BioPharma Ltd

China Registration ClassN/A

Develop Information

Active CompaniesPrestige BioPharma Ltd

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A